Duration: 3 Hour
The regulation and control of new or substantially changed medical devices for sale in the US is based on the 510(k), PMA or DeNovo submission process.
For decades, the regulation and control of new or substantially changed medical devices for sale in the United States (no matter where manufactured has been based on the 510(k), PMA or DeNovo submission and FDA review process. A 510(k) clearance for Class II devices or a Pre Market Approval for Class III devices is required prior to comercialization. IDEs are for investigational devices prior to submission. And DeNovo is for less risky Class III devices that could possibly be Class II. These submissions allow the FDA to review products as to substantial equivalence to existing products on the market (510(k)), or of a higher risk requiring clinicals (PMA).
The 510(k) process has had some recent modification to allow for newer technology (Breakthrough) or increased safety (STeP). And new Machine Learning and Artificial Intelligence features add additional complexity to the process. The data gathered during any human clinical trials of a device under an Investigational Device Exemption (IDE) becomes part of some submissions, primarily the PMA.
Why You Should Attend:
This seminar will discuss current US Federal law on the 510(k), IDE, DeNovo, and PMA and associated requirements for getting a new or substantially changed medical device through the US FDA review process and to market in the USA. US law and the FDA require that a device be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship an investigational device to clinical investigators in many states, it must seek an exemption from that legal requirement. The IDE is the means through which the sponsor technically obtains this exemption from the FDA.
The 510(k) program has recently been "modified" to encourage new technology and/or safer products to be submitted under the less severe 510(k) process to advance the state of the art, rather than the longer, more involved and more expensive PMA route when safety and efficacy issues remain substantially the same.
Areas Covered in the Session :
Who Should Attend: